EMA and Gray
Most recently, Mr. Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc (NYSE: GSK) since 2008 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. In both roles, he was instrumental in the launch, commercialization and strategic development of GSK's vaccine portfolio. Prior to the formation of GSK, Mr. Gray was with SmithKline Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the US, Vice President and Director of the Vaccines Business Unit in the US, and Vice President and General Manager of Pharmaceuticals in Canada. Mr. Gray received a Bachelor of Science degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School of Management in the UK.
Yeah, all of those rock solid creditials and he's going into his third month of doing nothing here.
Ooops! I forgot, he's got that HUGE deal coming up trolling and fluffing potential JMP investors.
Quick, add that credential to the list of all of those "feathers" you listed above.
Over 2 months and that's all he's got (jmp securities); My God, we are SO dead meat...........
The fundamental discovery by Drs. Mossman and Coffman of the specific types of T cells that helped either cellular or humoral (antibody-mediated) immunity revolutionized our understanding of how the immune system works, and led to major advances in designing therapies for infectious, inflammatory and allergic diseases and in vaccine design," said Dhaval Patel, HEAD, "Novartis" Institutes for Biological Research
( Europe and Global Head of Autoimmunity, Transplantation and Immunology.)